Advertisement

Clinical Reviews in Allergy & Immunology

, Volume 40, Issue 1, pp 60–65 | Cite as

Estrogen and Autoimmune Disease

  • Sara E. WalkerEmail author
Article

Abstract

Estrogenic hormones possess both immunostimulating and immunosuppressive properties. In systemic lupus erythematosus (SLE), pregnancy is associated with disease flares. In some situations, exogenous estrogen predisposes to development of new SLE, flares of preexisting SLE, and thromboses in susceptible individuals. In contrast, treatment with exogenous estrogen protects postmenopausal rheumatoid arthritis (RA) patients from active RA and osteoporosis. The search for estrogen-like compounds with anti-inflammatory properties may expand treatment options in RA.

Keywords

Autoimmunity Estrogen Systemic lupus erythematosus Rheumatoid arthritis Sjogren’s syndrome Multiple sclerosis 

References

  1. 1.
    Nalbandian G, Kovats S (2005) Estrogen, immunity & autoimmune disease. Curr Med Chem 5:85–91Google Scholar
  2. 2.
    Cutolo M, Capellino S, Sulli A et al (2006) Estrogens and autoimmune disease. Ann NY Acad Sci 1089:538–547CrossRefPubMedGoogle Scholar
  3. 3.
    Lang TJ (2004) Estrogen as an immunomodulator. Clin Immunol 113:224–230CrossRefPubMedGoogle Scholar
  4. 4.
    Cohen-Solal JFG, Jeganathan L, Kawabata D et al (2008) Hormonal regulation of B-cell function and systemic lupus erythematosus. Lupus 17:528–532CrossRefPubMedGoogle Scholar
  5. 5.
    Petri M (2008) Sex hormones and systemic lupus erythematosus. Lupus 17:412–415CrossRefPubMedGoogle Scholar
  6. 6.
    Maul RW, Gearhart PJ (2009) Women, autoimmunity, and cancer: a dangerous liaison between estrogen and activation-induced deaminase? J Exp Med 206:11–13CrossRefPubMedGoogle Scholar
  7. 7.
    Shim G-J, Kis LL, Warner M et al (2004) Autoimmune glomerulonephritis with spontaneous formation of splenic germinal centers in mice lacking the estrogen receptor alpha gene. Proc Natl Acad Sci U S A 101:1720–1724CrossRefPubMedGoogle Scholar
  8. 8.
    Bynote KK, Hackenbert JM, Korach KS et al (2008) Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB × NZW)Fl mice. Genes Immun 9:137–152CrossRefPubMedGoogle Scholar
  9. 9.
    McCarty DJ, Manzi S, Medsger TA Jr et al (1995) Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum 38:1260–1270CrossRefPubMedGoogle Scholar
  10. 10.
    Steinberg AD, Steinberg BJ (1985) Lupus disease activity associated with menstrual cycle. J Rheumatol 12:816–817PubMedGoogle Scholar
  11. 11.
    Mok CC, Lau CS, Ho CT et al (1999) Do flares of systemic lupus erythematosus decline after menopause? Scand J Rheumatol 28:357–362CrossRefPubMedGoogle Scholar
  12. 12.
    Mok CC, Wong RW, Lau CS et al (1999) Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum 42:1274–1280CrossRefPubMedGoogle Scholar
  13. 13.
    Costenbader KH, Feskanich D, Stampfer MJ et al (2007) Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 56:1251–1262CrossRefPubMedGoogle Scholar
  14. 14.
    Walker SE (2007) The importance of sex hormones in lupus. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus erythematosus, 7th edn. Williams & Wilkins, Baltimore, pp 273–285Google Scholar
  15. 15.
    Cooper GS, Dooley MA, Treadwell EL et al (2002) Hormonal and reproductive risk factors for development of systemic lupus erythematosus. Results of a population-based, case–control study. Arthritis Rheum 46:1830–1839CrossRefPubMedGoogle Scholar
  16. 16.
    Ostensen M (1999) Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus erythematosus. Ann NY Acad Sci 876:131–143CrossRefPubMedGoogle Scholar
  17. 17.
    Doria A, Iaccarino L, Sarzi-Puttini P et al (2006) Estrogens in pregnancy and systemic lupus erythematosus. Ann NY Acad Sci 1069:247–256CrossRefPubMedGoogle Scholar
  18. 18.
    Sanchez-Guerrero J, Karlson EW, Liang MH et al (1997) Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthrits Rheum 40:804–808CrossRefGoogle Scholar
  19. 19.
    Bl S, Reidenberg MM, West S et al (1994) Shingles, allergies, family medical history, oral contraceptives, and other potential risk factors for systemic lupus erythematosus. Am J Epidemiol 140:632–642Google Scholar
  20. 20.
    Petri M, Kim MY, Kalunian KC, Grossman J et al (2005) Combined oral contraceptives in women with systemic lupus erythematosus. New Engl J Med 353:2550–2558CrossRefPubMedGoogle Scholar
  21. 21.
    Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L et al (2005) A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 353:2539–2549CrossRefPubMedGoogle Scholar
  22. 22.
    US Preventive Services Task Force (2005) Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. Ann Int Med 142:885–860Google Scholar
  23. 23.
    Sanchez-Guerrero J, Liang MH, Karlson EW et al (1995) Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Int Med 122:430–433PubMedGoogle Scholar
  24. 24.
    Barrett C, Neylon N, Snaith ML (1986) Oestrogen-induced systemic lupus erythematosus. Br J Rheumatol 25:300–301CrossRefPubMedGoogle Scholar
  25. 25.
    Calvo-Alen FM, Bertoli AM, Bastian HM et al (2007) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA L II): relationship between vascular events and the use of hormone replacement therapy in postmenopausal women. J Clin Rheumatol 13:261–265CrossRefPubMedGoogle Scholar
  26. 26.
    Sanchez-Guerrero J, Gonzalez-Perez M, Durand-Darbajal M et al (2007) Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum 56:3070–3079CrossRefPubMedGoogle Scholar
  27. 27.
    Buyon JP, Petri MA, Kim MY et al (2005) The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Int Med 142:953–962PubMedGoogle Scholar
  28. 28.
    Grady D, Herrington D, Bittner V et al (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:49–57CrossRefPubMedGoogle Scholar
  29. 29.
    Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRefPubMedGoogle Scholar
  30. 30.
    Huong DLT, Wechsler B, Piette J-C et al (1996) Risks of ovulation-induction therapy in systemic lupus erythematosus. Br J Rheumatol 35:1184–1186CrossRefPubMedGoogle Scholar
  31. 31.
    Casoli P, Tumiati B, La Sala G (1997) Fatal exacerbation of systemic lupus erythematosus after induction of ovulation. J Rheumatol 24:1639–1640PubMedGoogle Scholar
  32. 32.
    Guballa N, Sammaritano L, Schwartzman S et al (2000) Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 43:550–556CrossRefPubMedGoogle Scholar
  33. 33.
    Du LTH, Wechsler B, Piette J-C (2003) Induction d’ovulation et lupus. Ann Med Interne 154:45–50Google Scholar
  34. 34.
    Silva CAA, Leal MM, Leone C et al (2002) Gonadal function in adolescents and young women with juvenile systemic lupus erythematosus. Lupus 11:419–425CrossRefPubMedGoogle Scholar
  35. 35.
    Shabanova SS, Ananieva LP, Alekberova ZS, Guzov II (2008) Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol 26:436–441PubMedGoogle Scholar
  36. 36.
    Cutolo M, Lahita RG (2005) Estrogens and arthritis. Rheum Dis Clin N Am 31:19–27CrossRefGoogle Scholar
  37. 37.
    Auborn KJ, Qi M, Yan XJ et al (2003) Lifespan is prolonged in autoimmune-prone (NZB/NZW) mice fed a diet supplemented with indole-3-carbinol. J Nutr 133:3610–3613PubMedGoogle Scholar
  38. 38.
    Apelgren LD, Bailey DL, Fouts RS et al (1996) The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRLlpr/lpr mice. Cell Immunol 173:55–63CrossRefPubMedGoogle Scholar
  39. 39.
    Sthoeger ZM, Zinger H, Mozes E (2002) Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZB×NZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann Rheum Dis 62:341–346CrossRefGoogle Scholar
  40. 40.
    Peeva E, Venkatesh J, Diamond B (2005) Tamoxifen blocks estrogen-induced B cell maturation but not survival. J Immunol 75:1415–1423Google Scholar
  41. 41.
    Greenstein BD, Dhaher YY, de Bridges EF (1993) Effects of an aromatase inhibitor on thymus and kidney and on oestrogen receptors in female MRL/MP-lpr/lpr mice. Lupus 2(2):221–225CrossRefPubMedGoogle Scholar
  42. 42.
    Rose E, Pillsbury DM (1944) Lupus erythematosus (erythematodes) and ovarian function: observations on a possible relationship, with report of six cases. Ann Int Med 21:1022–1034Google Scholar
  43. 43.
    Laroche M, Borg S, Lassoued S, De Lafontan B et al (2007) Joint pain with aromatase inhibitors: abnormal frequency of Sjogren’s syndrome. J Rheumatol 34:2259–2263PubMedGoogle Scholar
  44. 44.
    Cheong JL, Bucknall R (2009) Retinal vein thrombosis associated with a herbal phytoesrogen preparation in a susceptible patient. Postgrad Med J 81:266–267CrossRefGoogle Scholar
  45. 45.
    Bhattoa HP, Bettembuk P, Balogh A et al (2004) The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic, postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 15:396–404CrossRefPubMedGoogle Scholar
  46. 46.
    Sturgess AD, Evans DT, Mackay IR et al (1984) Effects of the oestrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus. J Clin Lab Immunol 13:11–14PubMedGoogle Scholar
  47. 47.
    Mok CC, To CH, Mak A et al (2005) Raloxifene for postmenopausal women with systemic lupus erythematosus. A pilot randomized controlled study. Arthritis Rheum 52:3997–4002CrossRefPubMedGoogle Scholar
  48. 48.
    Rider V, Li X, Peterson G, Dawson J et al (2006) Differential expression of estrogen receptors in women with systemic lupus erythematosus. J Rheumatol 33:1093–1101PubMedGoogle Scholar
  49. 49.
    Lee YJ, Shin KS, Kang SW et al (2004) Association of the oestrogen receptor alpha gene polymorphisms with disease onset in systemic lupus erythematosus. Ann Rheum Dis 63:1244–1249CrossRefPubMedGoogle Scholar
  50. 50.
    Johansson M, Arlestig L, Moller B et al (2005) Oestrogen receptor alpha gene polymorphisms in systemic lupus erythematosus. Ann Rheum Dis 64:1611–1617CrossRefPubMedGoogle Scholar
  51. 51.
    Abdou NI, Rider V, Greenwell C et al (2008) Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial. J Rheumatol 35:797–803PubMedGoogle Scholar
  52. 52.
    Fairweather D, Frisancho-Kiss S, Rose NR (2008) Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 173:600–609CrossRefPubMedGoogle Scholar
  53. 53.
    Brahn E, Banquerigo MN, Lee JK et al (2008) An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor. J Rheumatol 35:2119–2128CrossRefPubMedGoogle Scholar
  54. 54.
    Shoenfeld Y, Zangman-Goddard G, Stojanovich L et al (2008) The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases. IMAJ 10:8–12PubMedGoogle Scholar
  55. 55.
    Gerosa M, De Angelis V, Riboldi et al (2008) Rheumatoid arthritis: a female challenge. Women’s Health 4:195–201PubMedGoogle Scholar
  56. 56.
    Sokka T, Toloza S, Cutolo M et al (2009) Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arth Res Ther 11:R7Google Scholar
  57. 57.
    Straub RH, Harle P, Atzeni F et al (2005) Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy. J Rheumatol 32:1253–1257PubMedGoogle Scholar
  58. 58.
    Rovensky J, Kvetnansky R, Radikova Z et al (2005) Hormone concentrations in synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 23:292–296PubMedGoogle Scholar
  59. 59.
    Capellino S, Montagna P, Villaggio B et al (2007) Hydroxylated estrogen metabolites influence the proliferation of cultured human monocytes: possible role in synovial tissue hyperplasia. Clin Exp Rheumatol 26:904–909Google Scholar
  60. 60.
    Capellino S, Riepl B, Rauch L et al (2006) Quantitative determination of steroid hormone receptor positive cells in the synovium of patients with rheumatoid arthritis and osteoarthritis: is there a link to inflammation? Ann Rheum Dis 66:53–58CrossRefPubMedGoogle Scholar
  61. 61.
    Spector TD, Hochberg MC (1989) The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytical epidemiological studies using meta-analysis. Br J Rheumatol 28(Suppl):11–12PubMedGoogle Scholar
  62. 62.
    Hall GM, Daniels M, Huskisson EC et al (1994) A randomized controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. Ann Rheum Dis 53:112–116CrossRefPubMedGoogle Scholar
  63. 63.
    MacDonald AG, Murphy EA, Capell HA et al (1994) Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study. Ann Rheum Dis 53:54–57CrossRefPubMedGoogle Scholar
  64. 64.
    Forsblad d’Elia H, Larsen A, Mattsson L et al (2003) Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheum 30:1456–1463Google Scholar
  65. 65.
    Forsblad d’Elia H, Mattsson L, Ohlsson C et al (2003) Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor I. Arth Res Ther 5:R202–R209CrossRefGoogle Scholar
  66. 66.
    Forsblad d’Elia H, Carlsten H (2008) The impact of hormone replacement therapy on humoral and cell-mediated immune responses in vivo in post-menopausal women with rheumatoid arthritis. Scand J Immunol 68:661–667CrossRefPubMedGoogle Scholar
  67. 67.
    Maradit-Kremers H, Crowson CS, Nicola PJ et al (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52:402–411CrossRefPubMedGoogle Scholar
  68. 68.
    Jochems C, Lagerquist M, Hakansson C et al (2008) Long-term anti-arthritis and anti-osteopenic effects of raloxifene in established experimental postmenopausal polyarthritis. Clin Exp Immunol 152:593–597CrossRefPubMedGoogle Scholar
  69. 69.
    Harnish DC (2006) Estrogen receptor ligands in the control of pathogenic inflammation. Internat Immunol 6:1413–1423CrossRefGoogle Scholar
  70. 70.
    Carlsten H (2007) Interaction with estrogen receptors as treatment of arthritis and osteoporosis. In: Choi Y (ed) Osteoimmunology. Springer, New York, pp 83–92CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Departments of Internal Medicine and Pathology and Anatomical SciencesThe University of MissouriLas CrucesUSA

Personalised recommendations